Cardiovascular

San Ramon, CA-based BioVentrix is developing a hybrid transcatheter device for left ventricular remodeling after a heart attack. The pivotal trial for the device was originally scheduled to be completed by the end of the year. Now the trial is on...

Abbott Laboratories is making another go of it with reabsorbable stents. The Abbott Park, IL-based company is starting the launch of the LIFE-BTK clinical trial to evaluate the Esprit below-the-knee drug-eluting resorbable scaffold

CardioMech is developing a transcatheter system that it hopes could be used as an alternative to open-heart cardiac surgery to reduce or eliminate mitral regurgitation.

Edwards Lifesciences management acknowledged some recently cancelled cases due to COVID-19 resurgence, but still offers confident outlook for the back half of the year.

The Marlborough, MA-based company said it will have a limited launch of the Watchman FLX Left Atrial Appendage Closure (LAAC) technology and a broader launch in 4Q20.

The Santa Clara, CA-based company said the AMBULATE Same-Day Discharge will enroll 150 patients in up to 10 centers to evaluate the VASCADE MVP Venous Vascular Closure System.